The ALEX trial (40) demonstrated significantly improved PFS (34.8 months vs 10.9 months) and OS (NR vs 57.4 months; 5 years OS rate: 62.5% for alectinib vs 45.5% for crizotinib) with alectinib compared to crizotinib in treatment-naive ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.